Drug intelligence / Profile preview

EVO71

Development stage: Preclinical
Lead developer: Evox Therapeutics
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

EVO71 is an exosome-based enzyme replacement therapy being developed for the treatment of Fabry disease. Originally developed by Evox Therapeutics, the worldwide rights (excluding China) were licensed to Eli Lilly in October 2020. This therapy aims to address limitations of current Fabry disease treatments, such as poor central nervous system (CNS) penetration and immunogenicity, by utilizing Evox's exosome technology to deliver the therapeutic enzyme.

Targets

GLA (Alpha-galactosidase A)

Beyond the preview

Go deeper on EVO71.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVO71.

Explore the full profile